Miyachi, M., Tsuchiya, K., Hosono, A., Ogawa, A., Koh, K., Kikuta, A., . . . Hosoi, H. (2019). Phase II study of vincristine, actinomycin-D, cyclophosphamide and irinotecan for patients with newly diagnosed low-risk subset B rhabdomyosarcoma: A study protocol. Medicine (Baltimore), 98(52), e18344. https://doi.org/10.1097/MD.0000000000018344
Chicago-Zitierstil (17. Ausg.)Miyachi, Mitsuru, Kunihiko Tsuchiya, Ako Hosono, Atsushi Ogawa, Katsuyoshi Koh, Atsushi Kikuta, Junichi Hara, Satoshi Teramukai, und Hajime Hosoi. "Phase II Study of Vincristine, Actinomycin-D, Cyclophosphamide and Irinotecan for Patients with Newly Diagnosed Low-risk Subset B Rhabdomyosarcoma: A Study Protocol." Medicine (Baltimore) 98, no. 52 (2019): e18344. https://doi.org/10.1097/MD.0000000000018344.
MLA-Zitierstil (9. Ausg.)Miyachi, Mitsuru, et al. "Phase II Study of Vincristine, Actinomycin-D, Cyclophosphamide and Irinotecan for Patients with Newly Diagnosed Low-risk Subset B Rhabdomyosarcoma: A Study Protocol." Medicine (Baltimore), vol. 98, no. 52, 2019, p. e18344, https://doi.org/10.1097/MD.0000000000018344.